证券代码：301111 证券简称：粤万年青 公告编号：2025-055 广东万年青制药股份有限公司 关于控股股东、实际控制人之一致行动人股份减持计划的预 披露公告 本公司控股股东、实际控制人之一致行动人汕头市银康企业管理咨询合伙 企业（有限合伙）保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 广东万年青制药股份有限公司（以下简称"公司"）控股股东、实际控制人 之一致行动人汕头市银康企业管理咨询合伙企业（有限合伙）（以下简称"银康 管理"）持有公司股份 1,061,520 股（占公司总股本的 0.66%），计划在本公告 披露之日起 15 个交易日后的 3 个月内以集中竞价交易方式合计减持公司股份不 超过 1,061,520 股，即减持比例不超过公司总股本的 0.66%。 公司于近日收到公司股东银康管理出具的《股东减持计划告知函》，现将有 关情况公告如下： 一、股东的基本情况 1、股东名称：汕头市银康企业管理咨询合伙企业（有限合伙） 2、股东持股情况：截至本公告披露日，银康管理持有公司股份的总数量 ...

Group 1 - The core viewpoint of the news is that Guangdong Wannianqing Pharmaceutical Co., Ltd. is experiencing a decline in stock performance and financial metrics, with significant changes in financing activities and shareholder structure [1][2]. Group 2 - On November 6, Guangdong Wannianqing's stock price fell by 1.61%, with a trading volume of 30.78 million yuan. The financing buy-in amount was 2.14 million yuan, while the financing repayment was 4.38 million yuan, resulting in a net financing buy of -2.23 million yuan [1]. - As of November 6, the total balance of margin trading for Guangdong Wannianqing was 51.48 million yuan, which accounts for 1.88% of its circulating market value, indicating a low financing balance compared to the past year [1]. - The company had no short-selling activities on November 6, with a short-selling balance of 0.00 yuan, which is at a high level compared to the past year [1]. - As of September 30, the number of shareholders for Guangdong Wannianqing was 11,400, a decrease of 7.18% from the previous period, while the average circulating shares per person increased by 7.74% to 13,994 shares [2]. - For the period from January to September 2025, Guangdong Wannianqing reported an operating income of 228 million yuan, a slight decrease of 0.14% year-on-year, and a net profit attributable to shareholders of -8.13 million yuan, a significant decrease of 157.65% year-on-year [2]. - Since its A-share listing, Guangdong Wannianqing has distributed a total of 65.6 million yuan in dividends, with 40 million yuan distributed over the past three years [2].

Core Viewpoint - Guangdong Wannianqing Pharmaceutical Co., Ltd. is experiencing a decline in revenue and net profit, while its financing activities indicate a low level of market engagement and high short-selling potential. Group 1: Financial Performance - As of September 30, 2023, the company reported a revenue of 228 million yuan, a year-on-year decrease of 0.14% [2] - The net profit attributable to the parent company was -8.13 million yuan, representing a year-on-year decrease of 157.65% [2] Group 2: Shareholder and Market Activity - The number of shareholders decreased to 11,400, a reduction of 7.18% compared to the previous period [2] - The average number of circulating shares per shareholder increased to 13,994 shares, an increase of 7.74% [2] Group 3: Financing and Margin Trading - On November 5, 2023, the company had a financing buy-in amount of 3.50 million yuan, with a net financing buy of 944,100 yuan [1] - The total financing and margin trading balance was 53.72 million yuan, accounting for 1.93% of the circulating market value, which is below the 50th percentile level over the past year [1] - The company had no short-selling activity on November 5, 2023, with a short-selling balance of 0 yuan, indicating a high level of short-selling potential compared to the 90th percentile level over the past year [1] Group 4: Dividend Distribution - Since its A-share listing, the company has distributed a total of 65.60 million yuan in dividends, with 40 million yuan distributed over the past three years [3]

Group 1 - The core point of the article is that Guangdong Wannianqing Pharmaceutical Co., Ltd. announced the transfer of equity stakes in Shantou Beikang Enze Health Management Co., Ltd. to Huayin Group and Hangzhou Beikang Health Technology Group, resulting in a significant change in its ownership structure [1] - Guangdong Wannianqing's wholly-owned subsidiary, Wannianqing International Medical Management (Shantou) Group Co., Ltd., will transfer 60% of its stake in Beikang Enze for 12 million yuan and 10% for 2 million yuan, leading to a complete divestment from Beikang Enze [1] - Following the transaction, the ownership percentage of Beikang Enze held by Wannianqing International will decrease from 70% to 0%, and Beikang Enze will no longer be included in the company's consolidated financial statements [1] Group 2 - As of the report date, Guangdong Wannianqing has a market capitalization of 2.7 billion yuan [2] - For the fiscal year 2024, the revenue composition of Guangdong Wannianqing is projected to be 97.36% from pharmaceuticals, 1.53% from other sources, 0.57% from medical services and health management, and 0.53% from medicinal slices [1]

Core Viewpoint - The company reported a decline in revenue and a net loss for the first three quarters of 2025 compared to the previous year [1] Financial Performance - For the first three quarters of 2025, the company achieved an operating income of 228 million yuan, a year-on-year decrease of 0.14% [1] - The net profit attributable to shareholders of the listed company was a loss of 8.1295 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of 13.3186 million yuan [1] - The basic earnings per share were reported at -0.0508 yuan [1]

广东万年青制药股份有限公司 一、交易概述 关于转让控股子公司部分股权的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、广东万年青制药股份有限公司（以下简称"公司"）与广东合一云康医 药有限公司（以下简称"合一云康"）签署《股权转让协议》，拟将公司持有的 控股子公司海南万秘堂医药有限公司（以下简称"海南万秘堂"）51%的股权转 让给合一云康，转让价格为 3,373,543.10 元。交易完成后，公司不再持有海南 万秘堂股权，海南万秘堂不再纳入公司合并报表范围。公司将按照企业会计准则 的相关要求进行会计处理，预计将增加公司本期净利润，具体会计处理及影响数 以会计师年度审计确认后的结果为准。 2、本次股权转让事项不构成关联交易，也不构成《上市公司重大资产重组 管理办法》规定的重大资产重组。 证券代码：301111 证券简称：粤万年青 公告编号：2025-054 3、本次交易已经公司第三届董事会第九次会议审议通过，根据《深圳证券 交易所创业板股票上市规则》（以下简称"股票上市规则"）相关规定，本次交 易无需提交股东会审议。 1 合伙企业（有限合伙 ...

证券代码：301111 证券简称：粤万年青 公告编号：2025-053 广东万年青制药股份有限公司 关于全资子公司转让下属控股公司股权暨关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、广东万年青制药股份有限公司（以下简称"公司"）全资子公司万年青 国际医疗管理（汕头）集团有限公司（以下简称"国际医疗"）与汕头市华银集 团有限公司（以下简称"华银集团"）、杭州贝康健康科技集团有限公司（以下 简称"杭州贝康"）签署《股权转让协议》，拟将其持有的汕头贝康恩泽健康管 理有限公司（以下简称"贝康恩泽"）60%股权转让给华银集团，转让价格为 1,200 万元；将其持有的贝康恩泽 10%股权转让给杭州贝康，转让价格为 200 万元。交 易完成后，国际医疗持有贝康恩泽的股权比例由 70%变更为 0%，贝康恩泽不再纳 入公司合并报表范围。 2、本次交易股权转让价格系以国际医疗对贝康恩泽已实缴的注册资本 1,400 万元为定价依据，交易完成后预计将增加公司本期净利润，具体会计处理及影响 数以会计师年度审计确认后的结果为准。 3、鉴于交易对手方之一华 ...

证券代码：301111 证券简称：粤万年青 公告编号：2025-051 广东万年青制药股份有限公司 第三届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、 董事会会议召开情况 广东万年青制药股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日 在公司会议室以现场和通讯表决的方式召开公司第三届董事会第九次会议，此前 公司于 2025 年 10 月 24 日及 2025 年 10 月 28 日以电子邮件形式向全体董事发出 会议通知和补充通知。会议由公司董事长欧先涛先生召集并主持，本次会议应出 席的董事 8 名，实际出席的董事 8 名（其中董事欧泽庆先生、颜文孟先生和独立 董事李华青先生、郭剑先生以通讯方式出席并行使表决权）。公司高级管理人员 列席了本次会议。 本次董事会会议的召集、召开和表决程序符合《中华人民共和国公司法》《中 华人民共和国证券法》等法律、法规及公司章程等相关规定。 二、董事会会议审议情况 经全体与会董事认真审议，形成以下决议： （一）审议通过了《关于公司 2025 年第三季度报告的议案》 具体内容详见 ...

Financial Performance - The company's revenue for Q3 2025 was ¥73,634,583.96, a decrease of 3.58% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥904,655.63, representing a 9.84% increase in loss year-over-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥2,576,218.08, an increase in loss of 29.08% compared to the previous year[5]. - The basic and diluted earnings per share were both -¥0.0056, reflecting an 11.11% improvement in loss compared to the same period last year[5]. - Total operating revenue for the current period was ¥228,414,862.64, a slight decrease from ¥228,744,341.01 in the previous period, representing a decline of approximately 0.14%[18]. - Net profit for the current period was a loss of ¥11,571,407.58, compared to a profit of ¥14,027,447.67 in the previous period, indicating a significant decline[19]. Assets and Liabilities - Total assets at the end of the reporting period were ¥925,406,528.97, a decrease of 0.83% from the end of the previous year[5]. - The company's total assets decreased to ¥925,406,528.97 from ¥933,166,569.41, reflecting a reduction of approximately 0.8%[17]. - Current assets increased to ¥534,992,432.67 from ¥515,196,124.27, showing a growth of about 3.5%[16]. - The company's total liabilities rose to ¥173,199,761.72 from ¥166,415,829.70, an increase of approximately 4.7%[17]. - The company's total equity attributable to shareholders decreased by 2.11% to ¥748,207,707.63 compared to the end of the previous year[5]. - The company's total equity decreased to ¥752,206,767.25 from ¥766,750,739.71, a decline of about 1.9%[18]. Cash Flow - The company's cash flow from operating activities showed a net outflow of -¥1,820,451.14, which is an improvement of 85.25% compared to the previous year[5]. - The net cash flow from operating activities improved by 85.25%, reaching -1,820,451.14, attributed to reduced cash payments for purchasing Chinese medicinal materials and increased collections from accounts receivable[9]. - Cash inflow from operating activities totaled 246,300,713.20 CNY, an increase from 229,823,388.87 CNY in the previous period, representing an increase of approximately 7.5%[20]. - Cash outflow from operating activities was 248,121,164.34 CNY, compared to 242,164,560.28 CNY in the previous period, resulting in a net cash flow from operating activities of -1,820,451.14 CNY, an improvement from -12,341,171.41 CNY[20]. - The net cash flow from investing activities decreased by 172.00%, totaling -10,584,071.39, primarily due to a reduction in the scale of redeeming financial products[9]. - Cash inflow from investment activities was 113,220,646.68 CNY, down from 161,551,091.36 CNY in the previous period, a decrease of approximately 29.9%[21]. - Cash outflow from investment activities totaled 123,804,718.07 CNY, compared to 146,850,820.49 CNY in the previous period, leading to a net cash flow from investment activities of -10,584,071.39 CNY, a decline from 14,700,270.87 CNY[21]. - The net cash flow from financing activities improved by 62.47%, amounting to -5,108,269.87, mainly due to decreased dividend distribution expenses[9]. - Cash inflow from financing activities was 5,170,000.00 CNY, an increase from 3,400,000.00 CNY in the previous period, representing a growth of approximately 52.2%[21]. - Cash outflow from financing activities was 10,278,269.87 CNY, down from 17,010,060.96 CNY in the previous period, resulting in a net cash flow from financing activities of -5,108,269.87 CNY, an improvement from -13,610,060.96 CNY[21]. Investments and Business Activities - The company established a new health management company with a registered capital of RMB 1 million, holding a 19% stake, focusing on health diagnosis services[13]. - The company formed a joint venture for ophthalmic diagnosis services with a registered capital of RMB 2 million, also holding a 19% stake[13]. - The company transferred 100% equity of Jiangxi Yuanqifu Pharmacy Chain Co., Ltd. for RMB 750,000, which will no longer be included in the consolidated financial statements[14]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,433[11]. - The largest shareholder, Guangdong Jino Health Technology Co., Ltd., holds 45.00% of the shares, amounting to 72,000,000 shares[11]. Expenses and Financial Management - Financial expenses increased by 162.77% to ¥987,915.22 due to new business expansion and increased rental costs[8]. - Investment income decreased by 55.49% to ¥3,728,443.65, primarily due to reduced idle funds available for investment and losses from joint ventures[8]. - The fair value change income decreased by 70.51%, amounting to 461,965.43, primarily due to reduced idle funds available for financial management as the company expanded new businesses[9]. - Credit impairment losses increased by 122.28%, totaling -291,888.35, mainly due to an increase in accounts receivable leading to higher bad debt provisions[9]. - Research and development expenses for the current period were ¥6,675,637.43, slightly up from ¥6,416,666.62 in the previous period[18]. Audit Information - The company did not undergo an audit for the third quarter financial report[22].

证券代码：301111 证券简称：粤万年青 公告编号：2025-050 广东万年青制药股份有限公司 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 广东万年青制药股份有限公司（以下简称"公司"）于 2025 年 7 月 4 日在 巨潮资讯网（www.cninfo.com.cn）披露了《关于控股股东、实际控制人的一致 行动人股份减持计划的预披露公告》 （公告编号：2025-031），股东汕头市银 康企业管理咨询合伙企业（有限合伙）（以下简称"银康管理"）计划自该公告 披露之日起十五个交易日后的三个月内以集中竞价交易、大宗交易方式合计减持 公司股份不超过 4,800,000 股，即减持比例不超过公司总股本的 3.00%。 近日，公司收到银康管理出具的《告知函》,获悉银康管理于 2025 年 10 月 22 日，通过集中竞价及大宗交易的方式累计减持公司股份 2,915,900 股，占公司 总股本的比例为 1.8224375%。本次减持后，控股股东金欧健康及其一致行动人侨 银房地产、银康管理合计持有公司股份 85,061,520 股，占公司总股本的比例为 53.16345%,权益变动触及公司总股 ...